Evidence map›Paper›PMID 42146259›Full record

ArticleACS omega2026

Therapeutic Effects of Active Compounds from

Huan Yang, Jun Cao, Jianmin Li, Liming Zhu, Jinwen Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huan YangDepartment of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Medicine Research Center for Respiratory Rehabilitation in Hunan Province, Changsha, Hunan 410081, China.
Jun CaoDepartment of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Medicine Research Center for Respiratory Rehabilitation in Hunan Province, Changsha, Hunan 410081, China.
Jianmin LiDepartment of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Medicine Research Center for Respiratory Rehabilitation in Hunan Province, Changsha, Hunan 410081, China.
Liming ZhuDepartment of Pulmonary and Critical Care Medicine, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Clinical Medicine Research Center for Respiratory Rehabilitation in Hunan Province, Changsha, Hunan 410081, China.
Jinwen LuoDepartment of Cardiothoracic Surgery, Hunan Children's Hospital, the Affiliated Children's Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410007 China.ORCID https://orcid.org/0009-0000-9632-9107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammation plays a crucial role in the development and progression of pulmonary hypertension, leading to vascular remodeling, elevated pulmonary arterial pressure, and ultimately right heart failure. The limited long-term efficacy of vasodilator-based therapies highlights the urgent need for novel anti-inflammatory treatment strategies.

Identifiers

PMID42146259
PMCPMC13177022

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.